Durvalumab-induced organizing pneumonia in extensive-stage small cell lung cancer: A case report and literature review
The etoposide-carboplatin and anti-PD-L1 combination has become the standard-of-care for patients with extensive-stage small cell lung cancer (ES-SCLC). This combinational strategy is well tolerated with manageable immune-related adverse effects (irAEs). In this report, we presented a rare immediate...
Saved in:
| Main Authors: | Guoxin Wang, MD, Wenjie Yan, MD, Jun Cai, MD, Fang Zhang, MD, Tangfeng Lv, MD, Mingxiang Ye, MD, PhD |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Elsevier
2025-05-01
|
| Series: | Radiology Case Reports |
| Subjects: | |
| Online Access: | http://www.sciencedirect.com/science/article/pii/S1930043325000743 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Turtle Study: A Phase 2 Study of Durvalumab Plus Carboplatin and Etoposide in Elderly Patients With Extensive-Stage SCLC (LOGiK 2003)
by: Hidenobu Ishii, MD, PhD, et al.
Published: (2025-07-01) -
First-line durvalumab plus platinum–etoposide in Japanese patients with extensive-stage small-cell lung cancer
by: Eisuke Mochizuki, et al.
Published: (2025-01-01) -
Advances in Radiotherapy for Extensive-stage Small Cell Lung Cancer
in the Era of Immunotherapy
by: Tingting CHEN, et al.
Published: (2025-05-01) -
Recent Survival Gains in Stage IV NSCLC by Sociodemographic Strata
by: Oluwaseun F. Ayoade, MD, MSHA, et al.
Published: (2025-04-01) -
Development of a prognostic model for patients with extensive-stage small cell lung cancer undergoing immunotherapy and chemotherapy
by: Yunbin Gao, et al.
Published: (2025-03-01)